Zolpidem tartrate tablets are manufactured under the brand name Ambien by a number of US-based companies. There are two varieties: Ambien and Ambien CR. Zolpidem tartrate is the active component in both of these. The primary FDA-approved use of Ambien is the short-term treatment of insomnia in patients who have difficulty falling asleep. Zolpidem was also studied as a possible therapy for various neurologic conditions. Off-label use and successful case studies were found in the research; these were primarily associated with motor function abnormalities and consciousness issues. It demonstrates the possibility of developing novel treatment regimens for various ailments.